SLC6A3 and attention deficit-hyperactivity disorder: La Fougère et al. [44] aimed to evaluate whether the degree of dopamine transporter (DAT) binding in the striatum could predict the response to a 10-week treatment with MPH in a sample of 22 drug-naive patients with ADHD.